GLP-1s may lower breast cancer risk in women by 30%, new study suggests

Stay up to date with notifications from The IndependentNotifications can be managed in browser preferences.AllNewsSportCultureLifestyleWeight-loss jabs have risen in popularity (Alamy/PA) (Alamy/PA)A new study from the University of Pennsylvania Perelman School of Medicine found that women taking GLP-1 weight loss drugs like Ozempic and Wegovy had a 30 percent reduced risk of developing breast cancer. These findings build on previous research linking GLP-1 use to improved outcomes for various cancers, suggesting a broader potential for cancer prevention. The observational study analyzed health data from over 110,000 overweight American women aged 45 to 80 between 2022 and 2025, with 15,264 participants initially using GLP-1 medications. Researchers, including Dr. Elizabeth McDonald, emphasize that while the study does not definitively confirm a direct association, it warrants further investigation into these drugs as cancer prevention tools. The potential mechanisms behind this reduced risk include the drugs' ability to promote weight loss and reduce inflammation, both of which are known risk factors for breast cancer. In fullWomen taking GLP-1 drugs 30 percent less likely to develop breast cancer, researchers sayThank you for registeringPlease refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in

Raccontata dasciencedaily.comtheguardian.comdailymail.comindependent.co.uknewsbytesapp.comabcnews.comchannelnewsasia.comeuronews.commedpagetoday.comsciencealert.com